Agilent and FDA collaborate over salmonella
Agilent (Santa Clara, California, USA) has announced that it has entered into a Cooperative Research and Development Agreement with the US Food and Drug Administration (FDA) to develop new tools to detect and analyse pathogens in food.
Agilent (Santa Clara, California, USA) has announced that it has entered into a Cooperative Research and Development Agreement with the US Food and Drug Administration (FDA) to develop new tools to detect and analyse pathogens in food.
Salmonella, in particular, is being focused on and the goal is to develop a novel assay panel to identify subtypes of salmonella in food using mass spectrometry.
Eric W. Brown, PhD, director, division of microbiology, FDA, said, “This effort on the part of Agilent is of extraordinary importance to the FDA. We expect this collaboration will be an important step in the development of new and specific tools for tracking bacterial pathogens in foods.”
The collaboration is also seeking to improve DNA-based tools for confirming that seafood is correctly labelled by detecting such things as intentional mislabelling to avoid tariffs and import restrictions, or economic fraud where a less expensive species of fish is sold as a more expensive one.
Paul Zavitsanos, Agilent global food safety manager, commented, “We’re very pleased to be collaborating with the FDA because this work holds tremendous potential for solving some very challenging threats to the safety and integrity of the food supply.”
For more information please visit ref="http://www.agilent.com">www.agilent.com
New TRC Facility Accelerates Innovation and Delivery
April 25th 2025We’ve expanded our capabilities with a state-of-the-art, 200,000 sq ft TRC facility in Toronto, completed in 2024 and staffed by over 100 PhD- and MSc-level scientists. This investment enables the development of more innovative compounds, a broader catalogue and custom offering, and streamlined operations for faster delivery. • Our extensive range of over 100,000 high-quality research chemicals—including APIs, metabolites, and impurities in both native and stable isotope-labelled forms—provides essential tools for uncovering molecular disease mechanisms and exploring new opportunities for therapeutic intervention.
New Guide: Characterising Impurity Standards – What Defines “Good Enough?”
April 25th 2025Impurity reference standards (IRSs) are essential for accurately identifying and quantifying impurities in pharmaceutical development and manufacturing. Yet, with limited regulatory guidance on how much characterisation is truly required for different applications, selecting the right standard can be challenging. To help, LGC has developed a new interactive multimedia guide, packed with expert insights to support your decision-making and give you greater confidence when choosing the right IRS for your specific needs.
